Figure 4

Expression of SHARP1 and EMT markers in EC specimens. (A) IHC analysis of SHARP1, E-cadherin, N-cadherin, vimentin, snail, and jagged 1 in EC (stage I or III) or lymphatic metastases, and IHC staining without primary antibody were used as negative control (magnification: 200×). (B) Levels of SHARP1 in primary and metastatic tumors determined by semiquantitative analysis of IHC staining (*P = 0.0267). (C) Expression correlations between SHARP1 and E-cadherin, N-cadherin, vimentin, snail, and jagged 1. Statistical analyses were performed using the Spearman’s correlation coefficient test.